A fibrosarcoma is an inflamed (malignant) tumor that
originates from the connective fibrous tissue located at the ends of the bones
of the lower arm or leg and then proceeds to spread to other surrounding
tissues, causing extreme pain and complications. It's a form of cancer that
typically grows slowly over an extended period of time. Fibrosarcoma may
develop for several reasons, including: primary tumors at the facial
prominences on one or both sides of the heart; fibrosarcoma may develop in
response to an infection (such as those that occur in the stomach or
esophagus); tumors may also develop on other areas of the body other than the
skin. If you have any of these symptoms, you should contact your physician
immediately. However, since the symptoms of fibrosarcoma are similar to those
of other diseases, and because it's difficult to determine whether a disease
exists, most people with fibrosarcoma are sent for check-ups each year.
Market Dynamics
High prevalence of cancer is expected to propel
growth of the fibrosarcoma drugs market. For instance, according to the
American Cancer Society, in 2019, there will be an estimated 1,762,450 new
cancer cases diagnosed and 606,880 cancer deaths in the U.S. Moreover,
increasing funding in cancer R&D is also expected to aid in growth of the fibrosarcoma
drugs market. For instance, according to the National Cancer Research Institute
(NCRI), cancer research funding by NCRI partners reached around US$ 750 million
in 2018/19.
R&D in fibrosarcoma is expected to offer
lucrative growth opportunities for players in the fibrosarcoma
drugs market. For instance, in January 2021, researchers from Children's
Hospital of Philadelphia reported that neurotrophic tyrosine receptor kinase (NTRK)
fusions are more common in pediatric tumors and also involve a wider range of
tumors than adult cancers, information that could help prioritize screening for
NTRK fusions in pediatric cancer patients who might benefit from treatment with
TRK inhibitors.
Competitive Analysis
Major players operating in fibrosarcoma drugs market
include, Cadila Healthcare Limited, Bristol-Myers Squibb Company, Dr. Reddy's
Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Baxter International
Inc., Eli Lilly and Company, Cullgen Inc., Pfizer limited, Johnson &
Johnson., and Celon Laboratories Pvt. Ltd.
Major players operating in fibrosarcoma drugs market
are focused on R&D to expand their product portfolio. For instance, in
October 2020, Cullgen Inc. announced that the company’s internal program to
develop selective degraders that target key proteins within the TRK family has
been published by the Journal of Medicinal Chemistry.
Comments
Post a Comment